Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Ipamorelin | KPV | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 200-300 mcg administered 1-3 times daily via subcutaneous injection. | Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation. |
| Timing | Best administered at bedtime for synergy with natural GH peak. Also effective upon waking and post-workout. Always on empty stomach. | Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous. |
| Cycle Duration | 12-24 week cycles with 4-8 week breaks. | 4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as the first selective growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) agonist. Unlike other GHRPs, it selectively stimulates GH release without significantly affecting ACTH, cortisol, prolactin, or aldosterone — even at doses 200-fold above the ED50 for GH release. This selectivity profile is comparable to GHRH itself but operates through the distinct ghrelin receptor on pituitary somatotrophs.
Research indicates 200-300 mcg administered 1-3 times daily via subcutaneous injection.
Best administered at bedtime for synergy with natural GH peak. Also effective upon waking and post-workout. Always on empty stomach.
12-24 week cycles with 4-8 week breaks.
KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) that inhibits NF-kB signaling through a non-melanocortin receptor-mediated mechanism. It is transported intracellularly via the PepT1 transporter, where it stabilizes IkB-alpha and suppresses nuclear translocation of p65RelA by competing with importin-beta at the armadillo domain 7 and 8 binding site. It also reduces MAPK inflammatory signaling and IL-8 secretion in intestinal epithelial cells.
Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation.
Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous.
4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision.
Fast buy links (we may earn a small commission at no extra cost).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →